Freenome Acquires Oncimmune
Summary
The test has impacted the clinical journey of more than 200,000 people at high risk for lung cancer and those with indeterminate pulmonary nodules (IPN). Oncimmune Ltd’s pipeline of autoantibody targets for other cancer indications will augment Freenome’s multiomics platform with additional non-tumor-derived signals to capture a more comprehensive view of the tumor microenvironment. Led by Mike Nolan, CEO, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to detect cancer in its earliest stages using a standard blood draw. The company is completing the FDA verification and validation studies for its colorectal cancer screening test through the PREEMPT CRC trial. In parallel, Freenome has applied its expertise in cancer detection and machine learning to real-world data to develop population health solutions for payers and providers to complement its blood tests and support the entire patient’s care journey.
Classifications
AskAI Classifications
LabelsLinked Companies
